ribosomal protein L18a pseudogene 3Genealiases: RPL18A_6_1273 · bcm182
Q-omics provides the consensus-scored RPL18AP3 profile across patient tissues and cancer cell-line models. RPL18AP3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL18AP3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RPL18AP3 RNA expression shows 18,037 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where RPL18AP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL18AP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL18AP3 survival associations across molecular data types. RPL18AP3 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL18AP3 RNA expression–survival associations across cancer types. High RPL18AP3 expression shows unfavorable associations in ACC, LIHC, LUAD, OV and KIRP, but favorable associations in THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL18AP3 RNA expression.
This table summarizes RPL18AP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL18AP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL18AP3 shows lower tumor expression in BRCA and higher tumor expression in KIRC, COAD, LIHC, KIRP and LUSC. The KIRC box plot shows higher RPL18AP3 RNA expression in tumor versus normal tissue (log2 FC = +1.183, t-test p < 0.001).
This table shows molecular features associated with RPL18AP3 in patient tissues and cancer cell lines. In patient samples, RPL18AP3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
